Continuous Renal Replacement Therapy Market By Products (Systems, Consumables & Accessories {Dialysates & Replacement Fluids, Filters, Catheters, Bloodline Sets (Tubing Sets), Blood Warmer, Anticoagulant}), By Modality (Slow Continuous Ultra Filtration, Continuous Venovenous Hemofiltration, Continuous Venovenous Hemodialysis, Continuous Venovenous Hemodiafiltration), By Age Group (Adult, Pediatrics & Neonates), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers) and By Region; Global Insights & Forecast (2024 – 2030)

According to Intent Market Research, the Continuous Renal Replacement Therapy (CRRT) Market is expected to grow from USD 1.5 billion in 2023-e at a CAGR of 7.8% to touch USD 2.0 billion by 2030. The CRRT market is competitive, the prominent players in the global market include Asahi Kasei Medical, B. Braun, Baxter International, Cytosorbents, Fresenius Medical Care, Infomed SA, Medtronic, Nikkiso, NIPRO, Toray Medical. The market thrives due to factors such as the increasing incidence of acute kidney injury and the growing prevalence of diabetes and hypertension

CRRT devices are crucial in filtering and purifying blood when the kidneys are impaired or not functioning properly. Recent studies have highlighted a surge in critical illness and multi-organ failure, including acute kidney injury, attributed to SARS-CoV-2. This growing demand for CRRT is addressed by devices authorized under Emergency Use Authorizations (EUAs), encompassing components such as hemodialyzers/hemofilters, delivery units, bloodlines and tubing, and dialysate solutions.

The continual rise in the global intake of patients admitted to intensive/critical care units stands out as a primary driver fueling the growth of the CRRT market. Acute kidney injury, a prevalent complication among ICU patients, has become a significant global public health concern. The consistent application of this therapy significantly impacts the management of critically ill patients, particularly those with Acute Kidney Injury (AKI) stemming from severe complications such as cancer, diabetes, or cardiac surgery. The therapy, administered exclusively in the ICU, can extend for 24 hours or longer, depending on the patient's medical condition.

Notably, a substantial percentage of hospitalized patients in the UK experience AKI and 100,000 deaths each year are associated with AKI. The rising geriatric population worldwide has contributed to a surge in ICU admissions, driven by the increasing prevalence of acute and chronic health conditions that necessitate intensive care. In APAC, the number of older persons is projected to more than double, from 630 million in 2020 to about 1.3 billion by 2050, as stated by ‘United Nations Economic and Social Commission for Asia and the Pacific’. This are anticipated to drive the demand for CRRT, contributing to the expansion of the market throughout the forecast period.

Continuous Renal Replacement Therapy Market is Booming by Increasing Incidence of Acute Kidney Injury

CRRT market is influenced by the escalating incidence of AKI, driven by factors such as sepsis, cardiac surgery, and critical illnesses. This rise in AKI cases, particularly in an aging population, propels the demand for CRRT as a vital renal replacement therapy. Additionally, the market benefits from increasing clinical advantages associated with CRRT, notably the minimal risk of infection during the procedure. Technological advancements contribute to improved safety and patient outcomes, while robust clinical evidence supports CRRT's efficacy in managing critically ill patients with kidney dysfunction.

CRRT Systems for Continuous Management of AKI

In 2023, the systems segment accounted for the major market share in the CRRT market.  CRRT systems are pivotal medical devices employed in the continuous management of AKI and other renal disorders, particularly in critically ill patients within Intensive Care Units (ICUs). These systems operate continuously, ensuring a gradual and sustained removal of waste products and excess fluids from the bloodstream.

Continuous Venovenous Hemofiltration (CVVH) Segment Dominates the CRRT Market

CVVH provides a slow and continuous removal of waste products and excess fluids from the blood. Moreover, CRRT reduces the risk of rapid fluid shifts and hemodynamic instability compared to intermittent forms of dialysis.

Adult Segment Accounted for The Largest Share in the CRRT Market

Adults population grappling with AKI, increasing hospitalization rates among them, and the extensive availability of CRRT systems and disposables is driving the CRRT market growth. The adult demographic represents the fastest-growing age group in both developed and developing nations, contributing significantly to the robust demand for CRRT.

North America's Region Led by the Increasing Prevalence of AKI in the Region

North America holds the dominant position in the market due to the increasing prevalence of AKI among ICU patients, robust demand for therapy-related products surpassing other regions, and the presence of a well-established healthcare infrastructure. The region's high market share is further bolstered by increasing support from regulatory bodies and the significant presence of product manufacturers. Notably, Baxter International obtained 510(k) clearance from the US Food and Drug Administration in April 2022 for its ST Set designed used for this therapy, compatible with PrisMax or Prismaflex control units.

Major Industry Players Are Enhancing their Positions by Actively Developing CRRT Platforms

The market is characterized by intense competition due to the presence of numerous international and domestic players. The continuous renal replacement therapy market, in particular, is dominated by key players such as Asahi Kasei Medical, B. Braun, Baxter International, Cytosorbents, Fresenius Medical Care, Infomed SA, Medtronic, Nikkiso, NIPRO, and Toray Medical amongst others. These industry leaders primarily focus on acquiring smaller players and innovating their product lines to cater to changing consumer preferences and needs. The success of market players is heavily dependent on their ability to adapt to changing market trends and consumer preferences.

• In January 2023, Baxter announced a comprehensive strategic roadmap aimed at significantly elevating operational efficiency, fostering sustained long-term performance, expediting innovation, and generating enhanced value for its stakeholders. This strategic initiative encompasses the intent to establish an independent, publicly traded company by spinning off the ‘Renal Care and Acute Therapies’ global business units
• In December 2020, Medtronic launched the Carpediem cardio-renal pediatric dialysis emergency machine in the US. This is designed for use in cases of AKI or fluid overload, catering to patients requiring hemodialysis or hemofiltration therapy

Continuous Renal Replacement Therapy Market Coverage

The report provides key insights into the continuous renal replacement therapy market, and it focuses on technological developments, trends, and initiatives taken by the government in this sector. The report delves into market drivers, restraints, and opportunities, and analyses key players and the competitive landscape within the market.

Report Scope